Protein Expression FAQs

KREX™ utilises baculovirus expression system for the production of proteins of interest in insect cells. Although producing these recombinant baculoviruses are technically laborious, it may offers many advantages over other traditional systems: 1) Safety – baculoviruses are nonpathogenic, 2) Ease to scale-up – insect cell suspension cultures allows large-scale protein production in bioreactors, 3) Size – accomodate large genes, 4) High levels of protein expression – variety of efficient gene promoters and 5) Post-translational modification – proper protein folding, glycosylation, phosphorylation, acetylation and acylation.

KREX™ protein expression system utilises insect cell known as Sf9, a clonal isolate derived from the parental Spodoptera frugiperda cell line IPLB-Sf-21-AE.

Yes, we have successfully expressed proteins using different protein expression systems. Please email us at [email protected] for further discussion.

Depending on the size and complexity of the protein, the duration may vary between 3-6 months. Please email us at [email protected] for further discussion.

The cost is largely dependent on the size and the nature of the protein. Please email us at [email protected] for further discussion.

Crude lysates are subjected to SDS-PAGE and the biotinylated proteins were detected via Western blot.

Our final product is crude protein lysates with average concentration of total protein in our crude lysates is in the range of 2-3 μg/μl. However purified proteins are also available at an additional cost, please contact us at [email protected].

Please email us at [email protected] for further information.


High-throughput autoantibody profiling against 1600+ proteins

Quantification of autoantibodies to 200+ clinically relevant CT antigens

Simultaneous screening of 100+
wild-type and mutant p53

Multi-antigen, multi-domain
COVID-19 antibody test

Sengenics - Functional Proteomics | Krex Technology | Protein Microarray Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389